Cantel Medical (NYSE:CMD) Hits New 12-Month High at $93.12


Share on StockTwits

Cantel Medical Corp. (NYSE:CMD)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $93.12 and last traded at $86.47, with a volume of 23997 shares trading hands. The stock had previously closed at $84.66.

Several equities research analysts recently weighed in on CMD shares. BidaskClub upgraded shares of Cantel Medical from a “buy” rating to a “strong-buy” rating in a research note on Friday, December 11th. Zacks Investment Research raised shares of Cantel Medical from a “hold” rating to a “strong-buy” rating and set a $88.00 price target for the company in a report on Monday, December 21st. CJS Securities began coverage on shares of Cantel Medical in a report on Friday, October 23rd. They set an “outperform” rating and a $70.00 target price for the company. Sidoti lowered shares of Cantel Medical from a “buy” rating to a “neutral” rating in a report on Tuesday. Finally, Needham & Company LLC lowered shares of Cantel Medical from a “buy” rating to a “hold” rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, one has given a buy rating and two have given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $74.80.

The business’s 50-day moving average price is $78.90 and its two-hundred day moving average price is $60.65. The company has a market capitalization of $3.48 billion, a P/E ratio of 98.10, a PEG ratio of 1.67 and a beta of 1.54. The company has a debt-to-equity ratio of 1.28, a current ratio of 3.13 and a quick ratio of 2.31.

Cantel Medical (NYSE:CMD) last announced its quarterly earnings results on Tuesday, December 8th. The company reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of $0.36 by $0.54. The company had revenue of $297.03 million for the quarter, compared to analysts’ expectations of $292.50 million. Cantel Medical had a net margin of 3.38% and a return on equity of 11.19%. Research analysts expect that Cantel Medical Corp. will post 2.6 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. Engineers Gate Manager LP bought a new position in shares of Cantel Medical during the third quarter valued at about $1,088,000. Aperio Group LLC increased its stake in shares of Cantel Medical by 9.3% in the third quarter. Aperio Group LLC now owns 8,964 shares of the company’s stock worth $394,000 after purchasing an additional 759 shares in the last quarter. Raymond James & Associates purchased a new position in shares of Cantel Medical in the third quarter worth about $231,000. Comerica Bank increased its stake in shares of Cantel Medical by 38.1% in the third quarter. Comerica Bank now owns 73,329 shares of the company’s stock worth $3,818,000 after purchasing an additional 20,221 shares in the last quarter. Finally, Dupont Capital Management Corp increased its stake in shares of Cantel Medical by 271.1% in the third quarter. Dupont Capital Management Corp now owns 15,723 shares of the company’s stock worth $691,000 after purchasing an additional 11,486 shares in the last quarter. Institutional investors own 95.01% of the company’s stock.

About Cantel Medical (NYSE:CMD)

Cantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The company's Medical segment offers automated endoscope reprocessing systems; disinfectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets and transport systems; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services.

Featured Story: G-20

Receive News & Ratings for Cantel Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical and related companies with MarketBeat.com's FREE daily email newsletter.